Document is current
Any future updates will be listed below
-
Authors
Castelli, Lydia M.
Cutillo, Luisa
Souza, Cleide Dos Santos
Sanchez-Martinez, Alvaro
Granata, Ilaria
Lin, Ya-Hui
Myszczynska, Monika A.
Heath, Paul R.
Livesey, Matthew R.
Ning, Ke
Azzouz, Mimoun
Shaw, Pamela J.
Guarracino, Mario R.
Whitworth, Alexander J.
Ferraiuolo, Laura
Milo, Marta
Hautbergue, Guillaume M. https://orcid.org/0000-0002-1621-261X
-
Funding
Funding for this research was provided by:
Motor Neurone Disease Association (Hautbergue/Apr16/846-791, Apr16/848-791, AMBRoSIA 972-797)
Biotechnology and Biological Sciences Research Council (BB/S005277/1)
Medical Research Council (MR/R024162/1, MR/M010864/1, MC_UU_00015/6, MRC DPFS 129016, MR/S004920/1)
Royal Society International Research and Exchanges grant (IEC\R3\17010)
Fondation Thierry Latran (FTLAAP2016/ Astrocyte secretome)
Academy of Medical Sciences Springboard Award
H2020 European Research Council (DYNAMITO; 309742, ERC Advanced Award 294745)
Alzheimer's Research UK (ARUK-PG2018B-005)
NIHR Sheffield Biomedical Research Centre (IS-BRC-1215-20017)
- License Information
-
More Information
Article History
Received: 25 March 2021
Accepted: 16 July 2021
First Online: 10 August 2021
Declarations
:
: Informed consent was obtained from all patients before collection of fibroblasts under study STH16573 and Research Ethics Committee reference /YH/0330 (Prof Dame Pamela Shaw, University of Sheffield, UK). Induced pluripotent stem cell (iPSC) lines were obtained from Cedars-Sinai (USA), a nonprofit academic healthcare organization. Patient-derived cell lines are described in Table .
: Not applicable.
: GMH, MA, AJW and PJS have patents granted in the USA (US10/801027) and in Europe (EP3430143) for the use of inhibitors of SRSF1 to treat neurodegenerative disorders (WO2017207979A1). The authors declare no other relationships, conditions or circumstances that present a potential conflict of interest.
